Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis
Clinical trial NCT02301624 · COMPLETED
Trial details
- NCT number
- NCT02301624
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-11-12
- Primary completion
- 2019-01-15
- Enrollment
- 117
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.